Agenus Inc. (AGEN)
USD 1.5
(-6.25%)
USD 1.5
(-6.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 313.91 Million USD | -24.09% |
| 2022 | 413.55 Million USD | -11.25% |
| 2021 | 465.95 Million USD | 117.22% |
| 2020 | 214.51 Million USD | 38.1% |
| 2019 | 155.33 Million USD | 13.88% |
| 2018 | 136.4 Million USD | -1.45% |
| 2017 | 138.4 Million USD | -11.84% |
| 2016 | 156.98 Million USD | -35.19% |
| 2015 | 242.22 Million USD | 225.02% |
| 2014 | 74.52 Million USD | 113.94% |
| 2013 | 34.83 Million USD | 0.47% |
| 2012 | 34.67 Million USD | 75.05% |
| 2011 | 19.8 Million USD | -35.91% |
| 2010 | 30.9 Million USD | -32.63% |
| 2009 | 45.87 Million USD | -19.44% |
| 2008 | 56.94 Million USD | 27.86% |
| 2007 | 44.53 Million USD | -38.95% |
| 2006 | 72.95 Million USD | -29.96% |
| 2005 | 104.15 Million USD | -21.73% |
| 2004 | 133.05 Million USD | -5.01% |
| 2003 | 140.07 Million USD | 57.28% |
| 2002 | 89.06 Million USD | -4.79% |
| 2001 | 93.54 Million USD | -26.9% |
| 2000 | 127.96 Million USD | 128.51% |
| 1999 | 56 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 292.41 Million USD | 13.98% |
| 2024 Q1 | 256.55 Million USD | -18.27% |
| 2023 Q2 | 383.59 Million USD | -7.09% |
| 2023 Q1 | 412.85 Million USD | -0.17% |
| 2023 FY | 313.91 Million USD | -24.09% |
| 2023 Q3 | 335.47 Million USD | -12.54% |
| 2023 Q4 | 313.91 Million USD | -6.43% |
| 2022 FY | 413.55 Million USD | -11.25% |
| 2022 Q4 | 413.55 Million USD | -3.6% |
| 2022 Q3 | 429.01 Million USD | -5.95% |
| 2022 Q2 | 456.17 Million USD | 3.37% |
| 2022 Q1 | 441.3 Million USD | -5.29% |
| 2021 Q2 | 192.29 Million USD | -18.14% |
| 2021 Q1 | 234.91 Million USD | 9.51% |
| 2021 FY | 465.95 Million USD | 117.22% |
| 2021 Q3 | 437.63 Million USD | 127.58% |
| 2021 Q4 | 465.95 Million USD | 6.47% |
| 2020 Q4 | 214.51 Million USD | 4.91% |
| 2020 Q1 | 180.05 Million USD | 15.91% |
| 2020 Q2 | 185.78 Million USD | 3.18% |
| 2020 FY | 214.51 Million USD | 38.1% |
| 2020 Q3 | 204.48 Million USD | 10.06% |
| 2019 Q2 | 206.7 Million USD | -15.95% |
| 2019 Q3 | 174.8 Million USD | -15.43% |
| 2019 FY | 155.33 Million USD | 13.88% |
| 2019 Q4 | 155.33 Million USD | -11.14% |
| 2019 Q1 | 245.93 Million USD | 80.3% |
| 2018 FY | 136.4 Million USD | -1.45% |
| 2018 Q2 | 131.93 Million USD | 0.86% |
| 2018 Q4 | 136.4 Million USD | 4.54% |
| 2018 Q3 | 130.47 Million USD | -1.11% |
| 2018 Q1 | 130.81 Million USD | -5.48% |
| 2017 Q2 | 176.49 Million USD | -13.17% |
| 2017 Q4 | 138.4 Million USD | -7.28% |
| 2017 FY | 138.4 Million USD | -11.84% |
| 2017 Q1 | 203.26 Million USD | 29.48% |
| 2017 Q3 | 149.27 Million USD | -15.42% |
| 2016 Q3 | 174.84 Million USD | -11.0% |
| 2016 Q2 | 196.45 Million USD | -11.16% |
| 2016 Q1 | 221.13 Million USD | -8.71% |
| 2016 FY | 156.98 Million USD | -35.19% |
| 2016 Q4 | 156.98 Million USD | -10.21% |
| 2015 FY | 242.22 Million USD | 225.02% |
| 2015 Q1 | 117.32 Million USD | 57.42% |
| 2015 Q4 | 242.22 Million USD | -0.16% |
| 2015 Q3 | 242.6 Million USD | 34.7% |
| 2015 Q2 | 180.11 Million USD | 53.52% |
| 2014 Q2 | 100.18 Million USD | -7.49% |
| 2014 Q1 | 108.3 Million USD | 210.91% |
| 2014 FY | 74.52 Million USD | 113.94% |
| 2014 Q3 | 87.63 Million USD | -12.53% |
| 2014 Q4 | 74.52 Million USD | -14.95% |
| 2013 Q4 | 34.83 Million USD | -7.53% |
| 2013 FY | 34.83 Million USD | 0.47% |
| 2013 Q2 | 21.37 Million USD | -30.42% |
| 2013 Q1 | 30.71 Million USD | -11.42% |
| 2013 Q3 | 37.67 Million USD | 76.27% |
| 2012 Q1 | 33.2 Million USD | 67.64% |
| 2012 Q4 | 34.67 Million USD | 7.6% |
| 2012 FY | 34.67 Million USD | 75.05% |
| 2012 Q3 | 32.22 Million USD | -3.14% |
| 2012 Q2 | 33.26 Million USD | 0.19% |
| 2011 FY | 19.8 Million USD | -35.91% |
| 2011 Q4 | 19.8 Million USD | -18.72% |
| 2011 Q3 | 24.36 Million USD | 9.62% |
| 2011 Q2 | 22.23 Million USD | -15.88% |
| 2011 Q1 | 26.42 Million USD | -14.49% |
| 2010 Q3 | 36.61 Million USD | -13.04% |
| 2010 Q1 | 39.12 Million USD | -14.72% |
| 2010 Q2 | 42.1 Million USD | 7.63% |
| 2010 Q4 | 30.9 Million USD | -15.59% |
| 2010 FY | 30.9 Million USD | -32.63% |
| 2009 Q2 | 39.68 Million USD | -15.04% |
| 2009 Q3 | 51.35 Million USD | 29.39% |
| 2009 Q4 | 45.87 Million USD | -10.66% |
| 2009 FY | 45.87 Million USD | -19.44% |
| 2009 Q1 | 46.71 Million USD | -17.97% |
| 2008 FY | 56.94 Million USD | 27.86% |
| 2008 Q4 | 56.94 Million USD | -8.89% |
| 2008 Q3 | 62.5 Million USD | -13.36% |
| 2008 Q2 | 72.13 Million USD | 19.8% |
| 2008 Q1 | 60.21 Million USD | 35.21% |
| 2007 Q3 | 52.63 Million USD | -4.71% |
| 2007 FY | 44.53 Million USD | -38.95% |
| 2007 Q1 | 62.96 Million USD | -13.69% |
| 2007 Q4 | 44.53 Million USD | -15.39% |
| 2007 Q2 | 55.23 Million USD | -12.28% |
| 2006 FY | 72.95 Million USD | -29.96% |
| 2006 Q4 | 72.95 Million USD | 22.24% |
| 2006 Q3 | 59.67 Million USD | -13.67% |
| 2006 Q2 | 69.13 Million USD | -17.72% |
| 2006 Q1 | 84.01 Million USD | -19.33% |
| 2005 Q1 | 161.98 Million USD | 21.74% |
| 2005 Q4 | 104.15 Million USD | -14.43% |
| 2005 Q2 | 142.55 Million USD | -11.99% |
| 2005 FY | 104.15 Million USD | -21.73% |
| 2005 Q3 | 121.72 Million USD | -14.62% |
| 2004 Q2 | 167.82 Million USD | -7.23% |
| 2004 FY | 133.05 Million USD | -5.01% |
| 2004 Q3 | 152.09 Million USD | -9.38% |
| 2004 Q4 | 133.05 Million USD | -12.51% |
| 2004 Q1 | 180.9 Million USD | 29.14% |
| 2003 Q3 | 152.44 Million USD | 24.83% |
| 2003 Q1 | 135.23 Million USD | 51.84% |
| 2003 FY | 140.07 Million USD | 57.28% |
| 2003 Q4 | 140.07 Million USD | -8.11% |
| 2003 Q2 | 122.11 Million USD | -9.7% |
| 2002 Q4 | 89.06 Million USD | -14.36% |
| 2002 Q1 | 136.48 Million USD | 45.91% |
| 2002 Q2 | 117.82 Million USD | -13.68% |
| 2002 Q3 | 103.99 Million USD | -11.73% |
| 2002 FY | 89.06 Million USD | -4.79% |
| 2001 Q1 | 119.25 Million USD | -6.81% |
| 2001 Q2 | 111.87 Million USD | -6.19% |
| 2001 FY | 93.54 Million USD | -26.9% |
| 2001 Q4 | 93.54 Million USD | -11.42% |
| 2001 Q3 | 105.61 Million USD | -5.6% |
| 2000 Q2 | 115.19 Million USD | -3.22% |
| 2000 FY | 127.96 Million USD | 128.51% |
| 2000 Q3 | 112.09 Million USD | -2.68% |
| 2000 Q4 | 127.96 Million USD | 14.16% |
| 2000 Q1 | 119.02 Million USD | 0.0% |
| 1999 FY | 56 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 78.905% |
| Alkermes plc | 2.13 Billion USD | 85.305% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 91.804% |
| Aptorum Group Limited | 20.64 Million USD | -1420.89% |
| Ardelyx, Inc. | 297.57 Million USD | -5.489% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 58.995% |
| Bicycle Therapeutics plc | 595.34 Million USD | 47.272% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -325.922% |
| ChromaDex Corporation | 54.96 Million USD | -471.125% |
| Chimerix, Inc. | 212.77 Million USD | -47.534% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1010.316% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 28.813% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 85.92% |
| Precision BioSciences, Inc. | 159.78 Million USD | -96.465% |
| Dyadic International, Inc. | 8.21 Million USD | -3719.248% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -889.014% |
| Fortress Biotech, Inc. | 167.52 Million USD | -87.382% |
| Lantern Pharma Inc. | 43.64 Million USD | -619.199% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -94.57% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -2063.925% |
| Incyte Corporation | 6.78 Billion USD | 95.371% |
| IO Biotech, Inc. | 150.71 Million USD | -108.278% |
| Jaguar Health, Inc. | 50.76 Million USD | -518.389% |
| Novavax, Inc. | 1.85 Billion USD | 83.081% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 17.48% |
| Opthea Limited | 188.79 Million USD | -66.275% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 62.318% |
| ContextLogic Inc. | 423 Million USD | 25.789% |
| MiMedx Group, Inc. | 239.04 Million USD | -31.319% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -80.694% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -5972.169% |
| NextCure, Inc. | 129.41 Million USD | -142.557% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -481.881% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -754.673% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -871.837% |
| Vaxcyte, Inc. | 1.4 Billion USD | 77.704% |
| PDS Biotechnology Corporation | 59.39 Million USD | -428.561% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 50.993% |
| Pharming Group N.V. | 462.85 Million USD | 32.179% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -711.564% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 50.058% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1558.837% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1558.837% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -89.882% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -593.164% |
| Acelyrin, Inc. | 742.69 Million USD | 57.733% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -4665.99% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -4802.593% |
| Summit Therapeutics Inc. | 202.94 Million USD | -54.676% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -322.074% |
| Senti Biosciences, Inc. | 119.48 Million USD | -162.724% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -37.475% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -86.66% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -3699.02% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -6475.791% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 33.095% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -153.866% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -14.171% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 33.611% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -3006.512% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -46.342% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -27626.936% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 24.147% |
| Immix Biopharma, Inc. | 19.92 Million USD | -1475.46% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 15.164% |
| MEI Pharma, Inc. | 41.37 Million USD | -658.702% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -868.688% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 7.889% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -167.787% |
| Fortress Biotech, Inc. | 167.52 Million USD | -87.382% |
| Precigen, Inc. | 151.04 Million USD | -107.83% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -822.785% |
| AlloVir, Inc. | 190.79 Million USD | -64.528% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 16.613% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 37.988% |
| ImmuCell Corporation | 43.8 Million USD | -616.564% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 51.655% |
| Onconetix, Inc. | 88.82 Million USD | -253.42% |
| PureTech Health plc | 693.97 Million USD | 54.766% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -221.352% |
| Elevation Oncology, Inc. | 89.09 Million USD | -252.351% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -4961.48% |
| Seer, Inc. | 436.26 Million USD | 28.046% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -284.711% |
| Innoviva, Inc. | 1.24 Billion USD | 74.756% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -137.053% |
| ESSA Pharma Inc. | 149.12 Million USD | -110.507% |
| GlycoMimetics, Inc. | 45.31 Million USD | -592.713% |
| GT Biopharma, Inc. | 14.1 Million USD | -2124.913% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -1.955% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -29.876% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 33.48% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -519.194% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -229.699% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -49602.179% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 44.572% |
| Aptose Biosciences Inc. | 12.92 Million USD | -2329.189% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -1319.503% |
| Soligenix, Inc. | 9.79 Million USD | -3104.068% |
| Century Therapeutics, Inc. | 360.69 Million USD | 12.969% |
| Kura Oncology, Inc. | 448.93 Million USD | 30.076% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -15.346% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -1715.051% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -183.031% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -53.016% |
| Autolus Therapeutics plc | 375.38 Million USD | 16.375% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -24.749% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 11.62% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -538.918% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 52.519% |
| GRI Bio, Inc. | 2.95 Million USD | -10519.52% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -2859.984% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -84.097% |
| IGM Biosciences, Inc. | 423.41 Million USD | 25.861% |
| INmune Bio, Inc. | 57 Million USD | -450.715% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -41.081% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -273.967% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1101.955% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -4460.571% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -317.293% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -113.172% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -89.671% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 50.141% |
| Verastem, Inc. | 149.71 Million USD | -109.67% |
| Abeona Therapeutics Inc. | 64 Million USD | -390.474% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 38.707% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -103.236% |
| Histogen Inc. | 19.07 Million USD | -1545.85% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1285.919% |
| Surrozen, Inc. | 46.08 Million USD | -581.235% |
| Organovo Holdings, Inc. | 6.34 Million USD | -4844.29% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -7185.697% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -117.955% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -2559.829% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -317.06% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -3584.749% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 13.515% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -1634.863% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 26.895% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -2389.058% |
| Apollomics, Inc. | 55.38 Million USD | -466.763% |
| Amarin Corporation plc | 831.68 Million USD | 62.256% |
| Mesoblast Limited | 669.15 Million USD | 53.088% |
| Turnstone Biologics Corp. | 112.81 Million USD | -178.255% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 45.478% |
| Synaptogenix, Inc. | 31.11 Million USD | -908.923% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -2476.436% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 42.723% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -5245.692% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -4173.74% |
| Exelixis, Inc. | 2.94 Billion USD | 89.331% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1268.23% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 13.888% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 60.2% |
| NLS Pharmaceutics AG | 1.84 Million USD | -16899.135% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -3834.42% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -2036.189% |
| Gritstone bio, Inc. | 177.76 Million USD | -76.585% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -229.118% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -1657.408% |
| Avid Bioservices, Inc. | 336.55 Million USD | 6.728% |
| Insmed Incorporated | 1.32 Billion USD | 76.395% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -3160.301% |
| MediWound Ltd. | 66.45 Million USD | -372.341% |
| OmniAb, Inc. | 401.98 Million USD | 21.909% |
| Alector, Inc. | 621.82 Million USD | 49.518% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 12.462% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -5736.984% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -453.717% |
| Zai Lab Limited | 1.03 Billion USD | 69.708% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 34.39% |
| Aura Biosciences, Inc. | 255.07 Million USD | -23.067% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 58.147% |
| Immunic, Inc. | 54.29 Million USD | -478.119% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -17.913% |
| Veracyte, Inc. | 1.13 Billion USD | 72.411% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -2555.153% |
| FibroGen, Inc. | 423.52 Million USD | 25.882% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -8835.753% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -6527.384% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -5681.642% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 97.245% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -3465.168% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 39.335% |
| TG Therapeutics, Inc. | 329.58 Million USD | 4.756% |
| Galecto, Inc. | 38.22 Million USD | -721.181% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -994.689% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 92.796% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -33.351% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1163.638% |
| XBiotech Inc. | 227.24 Million USD | -38.14% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -229.118% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -120.135% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -9.792% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -145.496% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 17.824% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 78.946% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 13.959% |
| Vaxxinity, Inc. | 44.35 Million USD | -607.76% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 39.277% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -1586.858% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -2.905% |
| NexImmune, Inc. | 8.59 Million USD | -3552.721% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -2829.607% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -1732.813% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.051% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -1317.142% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -79925.748% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -81.108% |
| Ainos, Inc. | 31.84 Million USD | -885.852% |
| Pluri Inc. | 39.52 Million USD | -694.174% |
| Prothena Corporation plc | 696.38 Million USD | 54.922% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -11.074% |
| Celularity Inc. | 143.88 Million USD | -118.163% |
| Rallybio Corporation | 115.62 Million USD | -171.504% |
| Cue Biopharma, Inc. | 61.53 Million USD | -410.179% |
| MeiraGTx Holdings plc | 458.16 Million USD | 31.485% |
| Omeros Corporation | 378.26 Million USD | 17.013% |
| Humacyte, Inc. | 128.22 Million USD | -144.818% |
| Immunocore Holdings plc | 597 Million USD | 47.418% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -904.232% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -358.067% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 70.082% |
| CalciMedica, Inc. | 12.18 Million USD | -2476.225% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -23.758% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -83.674% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -0.925% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 44.47% |
| Pulmatrix, Inc. | 33.95 Million USD | -824.415% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1056.388% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -122.858% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 75.871% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -141.121% |
| Cytokinetics, Incorporated | 824.31 Million USD | 61.918% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -1386.119% |
| Nutriband Inc. | 7.51 Million USD | -4075.955% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -297.59% |
| Vor Biopharma Inc. | 209.82 Million USD | -49.605% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 95.654% |
| Evogene Ltd. | 51.1 Million USD | -514.299% |
| ProKidney Corp. | 420.55 Million USD | 25.357% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -472.489% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -3197.309% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 42.547% |
| CorMedix Inc. | 82.05 Million USD | -282.541% |
| BioLineRx Ltd. | 63.92 Million USD | -391.065% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 22.022% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1013.167% |
| Atai Life Sciences N.V. | 293.47 Million USD | -6.963% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -92.432% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -146.365% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 44.146% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -224.562% |
| MediciNova, Inc. | 66.26 Million USD | -373.688% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -256.93% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -6934.678% |
| GeoVax Labs, Inc. | 9.28 Million USD | -3281.51% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 46.635% |
| Biomea Fusion, Inc. | 199.92 Million USD | -57.014% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 83.506% |
| Mereo BioPharma Group plc | 66.49 Million USD | -372.057% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 35.288% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 48.781% |
| Absci Corporation | 234.48 Million USD | -33.876% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -4191.36% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 7.643% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -90.156% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 40.357% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -13.043% |
| Allakos Inc. | 243.61 Million USD | -28.859% |
| Imunon, Inc. | 21.91 Million USD | -1332.211% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -21.816% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 49.492% |
| BioAtla, Inc. | 119.65 Million USD | -162.342% |
| NLS Pharmaceutics AG | 1.84 Million USD | -16899.135% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -9648.851% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 51.168% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -227.214% |
| XOMA Corporation | 234.3 Million USD | -33.979% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -41.891% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -149.446% |
| aTyr Pharma, Inc. | 122.06 Million USD | -157.165% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -103.968% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 45.902% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 35.992% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -184.164% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -1971.0% |
| Akari Therapeutics, Plc | 4.35 Million USD | -7108.106% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1742.501% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 81.889% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -10078.808% |
| UroGen Pharma Ltd. | 178.31 Million USD | -76.048% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 33.314% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -56388.128% |
| Orgenesis Inc. | 14.55 Million USD | -2057.181% |
| Entera Bio Ltd. | 11.76 Million USD | -2568.194% |
| GH Research PLC | 226.3 Million USD | -38.715% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -473.944% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -192.186% |
| Xencor, Inc. | 952.69 Million USD | 67.05% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -3932.917% |
| Replimune Group, Inc. | 487.72 Million USD | 35.637% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -3789.351% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 51.59% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -10078.808% |
| Portage Biotech Inc. | 7.77 Million USD | -3935.39% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -6934.678% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -13.348% |
| OncoCyte Corporation | 74.89 Million USD | -319.154% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -15338.992% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -5324.786% |
| Purple Biotech Ltd. | 44.3 Million USD | -608.575% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -819.865% |
| scPharmaceuticals Inc. | 94.47 Million USD | -232.257% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -1639.616% |
| HilleVax, Inc. | 344.43 Million USD | 8.861% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -9783.911% |
| Tharimmune, Inc. | 10.94 Million USD | -2767.73% |
| Genprex, Inc. | 10.67 Million USD | -2841.852% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 36.736% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -226.137% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -12839.53% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -7436.129% |
| OKYO Pharma Limited | 1.54 Million USD | -20267.244% |
| Savara Inc. | 177.56 Million USD | -76.789% |
| Curis, Inc. | 77.28 Million USD | -306.192% |
| Daré Bioscience, Inc. | 21.28 Million USD | -1375.002% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -390.882% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -3782.179% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -1520.531% |
| BeiGene, Ltd. | 5.8 Billion USD | 94.593% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -2479.612% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 84.97% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 12.303% |
| Erasca, Inc. | 395.29 Million USD | 20.588% |
| bluebird bio, Inc. | 619.16 Million USD | 49.3% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -7160.842% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 95.412% |
| DBV Technologies S.A. | 182.98 Million USD | -71.55% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -7160.842% |
| Moderna, Inc. | 18.42 Billion USD | 98.296% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -1623.187% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -2609.417% |
| Molecular Templates, Inc. | 35.38 Million USD | -787.186% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -127.037% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 60.209% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -3.344% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -201.996% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 32.583% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -0.152% |
| MacroGenics, Inc. | 306.82 Million USD | -2.312% |
| RenovoRx, Inc. | 1.46 Million USD | -21312.892% |
| Adicet Bio, Inc. | 207.29 Million USD | -51.433% |
| Prime Medicine, Inc. | 193.85 Million USD | -61.935% |
| Aditxt, Inc. | 44.57 Million USD | -604.183% |
| Adagene Inc. | 115.72 Million USD | -171.249% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -6947.59% |
| Quantum-Si incorporated | 298.25 Million USD | -5.252% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 78.896% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -3971.968% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 10.638% |
| SciSparc Ltd. | 11.18 Million USD | -2707.306% |
| Vericel Corporation | 353.65 Million USD | 11.238% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -2470.401% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -451.687% |
| Generation Bio Co. | 374.75 Million USD | 16.236% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -23.265% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -97.969% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 8.042% |
| Invivyd, Inc. | 229.18 Million USD | -36.972% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 62.806% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -2479.548% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -72.111% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -1436.981% |
| 2seventy bio, Inc. | 565.42 Million USD | 44.482% |
| ADMA Biologics, Inc. | 329.18 Million USD | 4.638% |
| Clene Inc. | 52.34 Million USD | -499.746% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -434.463% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -141.669% |
| GeoVax Labs, Inc. | 9.28 Million USD | -3281.51% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 51.979% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -202.972% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -140.757% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -221.79% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -342.15% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -29.42% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 83.985% |
| Evaxion Biotech A/S | 12.88 Million USD | -2335.583% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -24.539% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 58.294% |
| Trevena, Inc. | 40.6 Million USD | -673.09% |
| Surrozen, Inc. | 46.08 Million USD | -581.235% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -38.988% |
| Cingulate Inc. | 3.49 Million USD | -8890.942% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -1787.744% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -377.87% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -2586.547% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -16.906% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 58.087% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -149.351% |
| Clearmind Medicine Inc. | 4.32 Million USD | -7159.13% |
| Kronos Bio, Inc. | 213.27 Million USD | -47.184% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -96.461% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -3566.947% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 14.811% |
| Statera Biopharma, Inc. | 21.16 Million USD | -1382.842% |
| ImmunityBio, Inc. | 504.45 Million USD | 37.771% |
| Korro Bio, Inc. | 221.66 Million USD | -41.617% |
| Kineta, Inc. | 10.28 Million USD | -2953.331% |
| BioVie Inc. | 25.2 Million USD | -1145.274% |
| Codexis, Inc. | 136.56 Million USD | -129.87% |
| Celularity Inc. | 143.88 Million USD | -118.163% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 50.592% |
| Celcuity Inc. | 191.21 Million USD | -64.164% |
| Virax Biolabs Group Limited | 5.48 Million USD | -5624.194% |
| Cibus, Inc. | 544.41 Million USD | 42.339% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -149.347% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -1428.003% |
| IN8bio, Inc. | 33.7 Million USD | -831.244% |
| Kodiak Sciences Inc. | 479.37 Million USD | 34.516% |
| Annexon, Inc. | 297.67 Million USD | -5.455% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -81.442% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -128.352% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -1395.322% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 89.501% |
| Eyenovia, Inc. | 28.77 Million USD | -990.757% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -36.171% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -4245.418% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -415.237% |
| Arcellx, Inc. | 825.13 Million USD | 61.956% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -284.523% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 32.094% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -920.855% |
| Moolec Science SA | 24.05 Million USD | -1205.182% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -1.221% |
| Geron Corporation | 394.07 Million USD | 20.342% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -208.635% |
| Royalty Pharma plc | 16.38 Billion USD | 98.084% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 47.239% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -4387.796% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -2510.0% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -38.863% |
| Humacyte, Inc. | 128.22 Million USD | -144.818% |
| Structure Therapeutics Inc. | 482.01 Million USD | 34.875% |
| 89bio, Inc. | 596.26 Million USD | 47.354% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -24.494% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -16868.27% |
| Genelux Corporation | 27.89 Million USD | -1025.419% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -251.121% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -36.824% |
| Notable Labs, Ltd. | 19.54 Million USD | -1506.433% |
| Liquidia Corporation | 120.43 Million USD | -160.658% |
| Mustang Bio, Inc. | 17.74 Million USD | -1669.321% |
| Immunovant, Inc. | 666.71 Million USD | 52.916% |
| Quantum-Si incorporated | 298.25 Million USD | -5.252% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -117.39% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -479.603% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -78.821% |
| Acasti Pharma Inc. | 73.3 Million USD | -328.258% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -6795.73% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1101.955% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 67.463% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -5948.516% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1277.96% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -508.323% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -73.729% |
| PepGen Inc. | 143.05 Million USD | -119.44% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -721.396% |
| United Therapeutics Corporation | 7.16 Billion USD | 95.62% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -1536.242% |
| Solid Biosciences Inc. | 164.93 Million USD | -90.321% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -5245.692% |
| Immuneering Corporation | 102.58 Million USD | -206.004% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -7185.697% |
| Silo Pharma, Inc. | 7.74 Million USD | -3952.508% |
| Belite Bio, Inc | 94.64 Million USD | -231.685% |
| XOMA Corporation | 234.3 Million USD | -33.979% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -34.618% |
| Bionomics Limited | 27.64 Million USD | -1035.346% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 21.796% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -192.317% |
| uniQure N.V. | 831.68 Million USD | 62.256% |
| Cassava Sciences, Inc. | 151.66 Million USD | -106.981% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -6947.59% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -14.615% |
| Forte Biosciences, Inc. | 38.98 Million USD | -705.318% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -7606.953% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -752.306% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -4245.418% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -8835.753% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -2555.554% |
| Altimmune, Inc. | 210.64 Million USD | -49.028% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 59.645% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -192.317% |
| Compugen Ltd. | 121.33 Million USD | -158.718% |
| Peak Bio, Inc. | 2.59 Million USD | -11990.248% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -82.161% |
| Benitec Biopharma Inc. | 52.21 Million USD | -501.251% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 8.175% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -802.749% |
| Zura Bio Limited | 100.84 Million USD | -211.289% |
| PolyPid Ltd. | 15.37 Million USD | -1942.109% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -163.16% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -802.749% |
| Instil Bio, Inc. | 325.63 Million USD | 3.598% |
| argenx SE | 4.54 Billion USD | 93.089% |
| Immunome, Inc. | 148.54 Million USD | -111.332% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -100.104% |
| Verona Pharma plc | 308.12 Million USD | -1.879% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -260.99% |
| Shattuck Labs, Inc. | 159.56 Million USD | -96.732% |
| CervoMed Inc. | 9.97 Million USD | -3047.78% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -66.571% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -2656.524% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -74.974% |
| Moolec Science SA | 24.05 Million USD | -1205.182% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -5031.41% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -81.511% |
| AnaptysBio, Inc. | 452.38 Million USD | 30.61% |
| Design Therapeutics, Inc. | 289.64 Million USD | -8.379% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -331.051% |
| NeurAxis, Inc. | 509.49 Thousand USD | -61512.214% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -5693.891% |
| Lumos Pharma, Inc. | 40.63 Million USD | -672.462% |
| Achilles Therapeutics plc | 161.45 Million USD | -94.426% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -260.99% |
| 180 Life Sciences Corp. | 5.25 Million USD | -5868.522% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -345.723% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -3566.947% |
| Nutriband Inc. | 7.51 Million USD | -4075.955% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -23.255% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -57.507% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -311.894% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -442.014% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 40.382% |
| Palisade Bio, Inc. | 14.05 Million USD | -2133.938% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -49.273% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 78.495% |
| Neurogene Inc. | 222.57 Million USD | -41.038% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 51.453% |
| AEON Biopharma, Inc. | 6.84 Million USD | -4486.019% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 30.709% |
| Sesen Bio, Inc. | 189.17 Million USD | -65.939% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -15.466% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -2189.352% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 59.773% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -17.573% |
| Athira Pharma, Inc. | 160.24 Million USD | -95.896% |
| Vaccinex, Inc. | 3.63 Million USD | -8545.359% |
| HCW Biologics Inc. | 28.51 Million USD | -1000.921% |
| XOMA Corporation | 234.3 Million USD | -33.979% |
| Nektar Therapeutics | 398.03 Million USD | 21.134% |
| Arvinas, Inc. | 1.3 Billion USD | 75.938% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1742.501% |
| Merus N.V. | 458.49 Million USD | 31.534% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -53.603% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -74.199% |
| Rezolute, Inc. | 132.73 Million USD | -136.492% |
| Clene Inc. | 52.34 Million USD | -499.746% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -2003.428% |
| BeyondSpring Inc. | 24.8 Million USD | -1165.37% |
| Synlogic, Inc. | 75.55 Million USD | -315.504% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -2546.375% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -3252.339% |
| Peak Bio, Inc. | 2.59 Million USD | -11990.248% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -79.55% |
| Krystal Biotech, Inc. | 818.35 Million USD | 61.641% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -30.559% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 56.749% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -8675.447% |
| MannKind Corporation | 475.19 Million USD | 33.941% |
| Ikena Oncology, Inc. | 192.09 Million USD | -63.418% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -2247.189% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -169.363% |
| Gossamer Bio, Inc. | 311.91 Million USD | -0.64% |
| CohBar, Inc. | 16.36 Million USD | -1818.119% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -792.737% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -4191.36% |
| Legend Biotech Corporation | 1.84 Billion USD | 83.019% |
| Mural Oncology plc | 301.74 Million USD | -4.033% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -905.648% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -5426.243% |
| Disc Medicine, Inc. | 367.99 Million USD | 14.697% |
| Champions Oncology, Inc. | 26.13 Million USD | -1101.259% |
| REGENXBIO Inc. | 573.97 Million USD | 45.308% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -11491.697% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -103.33% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -2499.569% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 7.682% |
| Vaxart, Inc. | 91.83 Million USD | -241.841% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -424.028% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -111.636% |
| Cellectis S.A. | 334.27 Million USD | 6.09% |
| Longeveron Inc. | 12.17 Million USD | -2477.706% |
| Repare Therapeutics Inc. | 253.9 Million USD | -23.636% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 90.384% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -56.295% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 84.97% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -19217.723% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -13.036% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -92.469% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -126.253% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1129.97% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.619% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 72.796% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -2470.401% |
| Veru Inc. | 50.59 Million USD | -520.431% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -589.116% |
| Cingulate Inc. | 3.49 Million USD | -8890.942% |
| Passage Bio, Inc. | 150.54 Million USD | -108.518% |
| Context Therapeutics Inc. | 16.06 Million USD | -1854.294% |
| Exicure, Inc. | 11.58 Million USD | -2610.82% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 16.523% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -94.203% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -1696.663% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 5.66% |
| Nuvalent, Inc. | 732.38 Million USD | 57.138% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -2000.584% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -250.529% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -2112.057% |
| OmniAb, Inc. | 401.98 Million USD | 21.909% |
| Anew Medical, Inc. | 19.45 Million USD | -1513.455% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1074.536% |
| Lipocine Inc. | 23 Million USD | -1264.776% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -124.533% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -2.732% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -273.967% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -158.28% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -3856.055% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 64.42% |
| Ocugen, Inc. | 64.54 Million USD | -386.332% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -152.056% |
| Q32 Bio Inc. | 306.11 Million USD | -2.546% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -7359.91% |
| Alumis Inc. Common Stock | 89.61 Million USD | -250.302% |
| Equillium, Inc. | 50.53 Million USD | -521.241% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -317.465% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -660.567% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -18356.21% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1100.845% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -387.132% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -8322.417% |
| Dominari Holdings Inc. | 57.55 Million USD | -445.386% |
| Edesa Biotech, Inc. | 8.89 Million USD | -3430.906% |
| vTv Therapeutics Inc. | 11.01 Million USD | -2749.092% |
| Bio-Techne Corporation | 2.81 Billion USD | 88.841% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 66.502% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 61.314% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -13.055% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -652.753% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 52.978% |
| Nkarta, Inc. | 378.88 Million USD | 17.148% |
| BioCardia, Inc. | 2.98 Million USD | -10409.307% |
| Iterum Therapeutics plc | 26.25 Million USD | -1095.449% |